glp 1 drops dosage GLP-1 Oral GLP-1 Medication Tips and Resources

Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released phase 2 trial results demonstrating 25% weight loss in half of people with #obesity

Yabut and Drucker discuss clinical and preclinical evidence about the potential roles of GLP-1 medicines on cancer incidence, development and therapy and speculate about their mechanism on cancer cells and the tumor microenvironment.

The overall safety profile appears favorable, with serious adverse events being relatively rare and consistent with the broader GLP-1 receptor agonist class

however, scientific evidence from clinical trials is scarce

GLP-1 agonists are regularly prescribed by doctors for patients with Type 2 Diabetes. And now theyre the next big thing in the weight loss world.

subscription funnel strategy support